Richard Bernstein, MD, PhD - Factoring a Balanced Efficacy and Safety Profile Into the Equation: Exploring FXIa Inhibitors in Stroke Prevention

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

1AM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

Deeper Lore: 315 (32, 196, & 204) 2 min · 24 Sep 2026 · Lore

The Farmhouse Edit: Create a Home That Works for You, Not Against You | Simplifying Motherhood with Sarah Therése 1h 4m · 24 Sep 2026 · Simple Farmhouse Life

AEE 2693: Back to the Future! How to Connect Over Classic Films 18 min · 24 Sep 2026 · All Ears English Podcast

Jake Humphrey on Grief, The Trauma Of Childhood Bullying & His Mission To Save Young Men 1h 1m · 24 Sep 2026 · Begin Again with Davina McCall

Power, water and place: what makes the optimal data center location? | Andrew DesRochers 20 min · 24 Sep 2026 · Technology Now

Report any issue

Source

Recorded18 Jun 2024

Publisherc.answersincme.com ↗

Handlerec:10296298

Show notes

Please visit answersincme.com/XFG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in vascular neurology discusses the data and the implications for inhibiting coagulation factor XIa (FXIa) as a therapeutic option in stroke prevention. Upon completion of this activity, participants should be better able to: Identify the rationale for inhibiting FXIa as a therapeutic option in stroke prevention; Describe the latest clinical data for oral FXIa inhibitors in stroke prevention; and Review the implications of the latest FXIa inhibitor data for the future of stroke prevention.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in